title: Phenobarbital treatment in a patient with resistant alcohol withdrawal syndrome.
abstract: Alcohol withdrawal syndrome (AWS) is a major cause of morbidity and mortality in the acute care setting. We describe a 28-year-old man who was brought to the emergency department with a new-onset seizure and clinical signs and symptoms consistent with advanced delirium tremens. A symptom-triggered intensive care unit treatment protocol consisting of a benzodiazepine and antiadrenergic agents was started. The manifestations of delirium tremens persisted with titration of a lorazepam infusion in excess of 40 mg/hour. Intravenous phenobarbital was administered in escalating doses of 65 mg followed by 130 mg 15 minutes later, resulting in control of severe agitation in the face of benzodiazepine resistance. Subsequent scheduled phenobarbital administration allowed for a successful and orderly weaning of the continuous benzodiazepine infusion and adjunctive agents used in AWS management. With continued clearing of consciousness, the patient was successfully discharged. The administration of phenobarbital in this patient allowed improved symptom control, minimized the potential for propylene glycol toxicity, was not associated with respiratory depression, and facilitated successful weaning of benzodiazepines. Barbiturates offer a mechanism of action that is different from that of benzodiazepines. Although the cornerstone of treatment for AWS remains benzodiazepines, this case highlights the potential utility of phenobarbital in patients with resistant AWS.
authors: Department of Internal Medicine, Pulmonary and Critical Care Division, Good Samaritan Hospital, Cincinnati, Ohio, USA. Christopher_hayner@trihealth.com
authors: Christopher E
authors: CE
authors: Hayner
authors: Nancy L
authors: NL
authors: Wuestefeld
authors: Pamela J
authors: PJ
authors: Bolton
mesh_terms: D000328:Adult; D000430:Alcohol Withdrawal Delirium / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000627:therapeutic use*; D008140:Lorazepam / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D014677:Pharmaceutical Vehicles / Q000009:adverse effects; D010634:Phenobarbital / Q000008:administration & dosage / Q000627:therapeutic use*; D019946:Propylene Glycol / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D006993:Hypnotics and Sedatives; D014677:Pharmaceutical Vehicles; D019946:Propylene Glycol; D008140:Lorazepam; D010634:Phenobarbital